Teresa Vezza

Dr. Teresa Vezza

CIBER-EHD, Department of Pharmacology, Center for Biomedical Research (CIBM), University of Granada, Granada, Spain.
+1
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2016 in Nutrients
Verified
Journal Article
Open access
PDF file
TVTeresa Vezza
Teresa Vezza
ARAlba Rodríguez-Nogales
Alba Rodríguez-Nogales
FAFrancesca Algieri
Francesca Algieri
MUMaria Pilar Utrilla
Maria Pilar Utrilla
Maria Elena Rodriguez-CabezasMaria Elena Rodriguez-Cabezas
Maria Elena Rodriguez-Cabezas
Julio GalvezJulio Galvez
Julio Galvez
Inflammatory bowel disease (IBD) is characterized by chronic inflammation of the intestine that compromises the patients’ life quality and requires sustained pharmacological and surgical treatments. Since their etiology is not completely understood, non-fully-efficient drugs have been developed and those that have shown effectiveness are not devoid of quite important adverse effects that impair their long-term use. In this regard, a growing body of evidence confirms the health benefits of flavonoids. Flavonoids are compounds with low molecular weight that are widely distributed throughout the vegetable kingdom, including in edible plants. They may be of great utility in conditions of acute or chronic intestinal inflammation through different mechanisms including protection against oxidative stress, and preservation of epithelial barrier function and immunomodulatory properties in the gut. In this review we have revised the main flavonoid classes that have been assessed in different experimental models of colitis as well as the proposed mechanisms that support their beneficial effects.

28 July 2017 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
ARAlba Rodríguez‐Nogales
Alba Rodríguez‐Nogales
FAFrancesca Algieri
Francesca Algieri
JMJosé Garrido Mesa
José Garrido Mesa
TVTeresa Vezza
Teresa Vezza
MUM. Pilar Utrilla
M. Pilar Utrilla
Julio GalvezJulio Galvez
Julio Galvez

1 November 2018 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
ARAlba Rodríguez-Nogales
Alba Rodríguez-Nogales
FAFrancesca Algieri
Francesca Algieri
JGJosé Garrido-Mesa
José Garrido-Mesa
TVTeresa Vezza
Teresa Vezza
MUM. Pilar Utrilla
M. Pilar Utrilla
Julio GalvezJulio Galvez
Julio Galvez

12 December 2020 in Antioxidants
Verified
Journal Article
Open access
PDF file
TVTeresa Vezza
Teresa Vezza
FCFrancisco Canet
Francisco Canet
AMAranzazu de Marañón
Aranzazu de Marañón
Celia BañulsCelia Bañuls
Celia Bañuls
Milagros RochaMilagros Rocha
Milagros Rocha
Víctor M. VíctorVíctor M. Víctor
Víctor M. Víctor
Obesity and its related disorders, such as diabetes and cardiovascular risk, represent an emerging global health issue. Even though genetic factors seem to be the primary actors in the development and progression of these diseases, dietary choices also appear to be of crucial importance. A healthy diet combined with physical activity have been shown to ameliorate glycaemic levels and insulin sensitivity, reduce body weight and the risk of chronic diseases, and contribute to an overall improvement in quality of life. Among nutrients, phytosterols have become the focus of growing attention as novel functional foods in the management of metabolic disorders. Phytosterols are natural plant compounds belonging to the triterpene family and are structurally similar to cholesterol. They are known for their cholesterol-lowering effects, anti-inflammatory and antioxidant properties, and the benefits they offer to the immune system. The present review aims to provide an overview of these bioactive compounds and their therapeutic potential in the fields of obesity and metabolic disorders, with special attention given to oxidative stress, inflammatory status, and gut dysbiosis, all common features of the aforementioned diseases.

27 December 2019 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
IRIñaki Robles-Vera
Iñaki Robles-Vera
MTMarta Toral
Marta Toral
NVNestor de la Visitacion
Nestor de la Visitacion
MSManuel Sanchez
Manuel Sanchez
Manuel Gómez-GuzmánManuel Gómez-Guzmán
Manuel Gómez-Guzmán
Juan DuarteJuan Duarte
Juan Duarte
Background and Purpose: Hypertension is associated with gut dysbiosis. Here we have evaluated the effects of the angiotensin receptor antagonist losartan on gut microbiota in spontaneously hypertensive rats (SHR) to assess their contribution to its antihypertensive effects.Experimental Approach: Twenty‐week‐old Wistar Kyoto rats (WKY) and SHR were treated with losartan for 5 weeks (SHR‐losartan). Faecal microbiota transplantation (FMT) was performed from donor SHR‐losartan group to recipient untreated‐SHR. Blood pressure (BP) was measured using tail‐cuff plethysmography. Composition of the gut microbiota was assessed by amplification of the V3‐V4 region of 16S rRNA gene. T cells were analysed in gut/aorta by flow cytometry.Key Results: Faeces from SHR showed gut dysbiosis, characterised by higher Firmicutes/Bacteroidetes ratios, lower acetate‐ and higher lactate‐producing bacteria, and lower levels of strict anaerobic bacteria, effects which were restored to normal by losartan. Improvement of gut dysbiosis was linked to higher colonic integrity and lower sympathetic drive in the gut. In contrast, hydralazine reduced BP, but it neither restored gut dysbiosis nor colonic integrity. FMT from SHR‐losartan to SHR reduced BP, improved the aortic endothelium‐dependent relaxation to ACh, and reduced NADPH oxidase activity. These vascular changes were accompanied by both increased Treg and decreased Th17 cell populations in the vascular wall.Conclusion and Implications: In SHR, losartan treatment reduced gut dysbiosis and sympathetic drive in the gut, thus improving gut integrity. The changes induced by losartan in gut microbiota contributed, in part, to protecting the vasculature and reducing BP, possibly by modulating the immune system in the gut.

17 May 2022 in Redox Biology
Verified
Journal Article
Open access
AMAranzazu M. de Marañón
Aranzazu M. de Marañón
PDPedro Díaz-Pozo
Pedro Díaz-Pozo
FCFrancisco Canet
Francisco Canet
NDNoelia Díaz-Morales
Noelia Díaz-Morales
ZAZaida Abad-Jiménez
Zaida Abad-Jiménez
Víctor M. VíctorVíctor M. Víctor
Víctor M. Víctor
Type 2 diabetes is a chronic metabolic disease that affects mitochondrial function. In this context, the rescue mechanisms of mitochondrial health, such as mitophagy and mitochondrial biogenesis, are of crucial importance. The gold standard for the treatment of type 2 diabetes is metformin, which has a beneficial impact on the mitochondrial metabolism. In this study, we set out to describe the effect of metformin treatment on mitochondrial function and mitophagy in peripheral blood mononuclear cells (PBMCs) from type 2 diabetic patients. We performed a preliminary cross-sectional observational study complying with CONSORT requirements, for which we recruited 242 subjects, divided into 101 healthy volunteers, 93 metformin-treated type 2 diabetic patients and 48 non-metformin-treated type 2 diabetic patients. Mitochondria from the type 2 diabetic patients not treated with metformin displayed more reactive oxygen species (ROS) than those from healthy or metformin-treated subjects. Protein expression of the electron transport chain (ETC) complexes was lower in PBMCs from type 2 diabetic patients without metformin treatment than in those from the other two groups. Mitophagy was altered in type 2 diabetic patients, evident in a decrease in the protein levels of PINK1 and Parkin in parallel to that of the mitochondrial biogenesis protein PGC1α, both of which effects were reversed by metformin. Analysis of AMPK phosphorylation revealed that its activation was decreased in the PBMCs of type 2 diabetic patients, an effect which was reversed, once again, by metformin. In addition, there was an increase in the serum levels of TNFα and IL-6 in type 2 diabetic patients and this was reversed with metformin treatment. These results demonstrate that metformin improves mitochondrial function, restores the levels of ETC complexes, and enhances AMPK activation and mitophagy, suggesting beneficial clinical implications in the treatment of type 2 diabetes.